Pharmacy Update: Ranitidine and NDMA

Pharmacy Update: Ranitidine and NDMA

September 25th, 2019 | NewsPharmacy Pearls

Your AHP pharmacists would like to provide you with a follow-up to the pharmacy update released last week regarding ranitidine and NDMA. This past Monday, September 23, Sandoz Inc voluntarily recalled all generic ranitidine hydrochloride capsules (150mg and 300mg) in the U.S. at the consumer level due to the likely human carcinogen NDMA detected in some batches. The recall comes a week after Sandoz halted all distribution of generic ranitidine.

To date, there have not been any reports of adverse events related to the use of the recalled product. Sandoz continues to investigate more samples of ranitidine internally. Retail pharmacies and distributors are immediately stopping dispensing and distribution at this time.

Patients current taking generic ranitidine (Rx or OTC) are being asked to continue to take their medication and speak to their physician or pharmacist for alternate treatment options. If you have a patient who is affected by this recall, consider advising your patient to switch to famotidine. For a list of lot numbers and NDCs affected by this recall, click here.

We will keep you updated as any new information surfaces regarding this recall.

As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.